Literature DB >> 22286205

Spontaneous modifications of contrast enhancement in childhood non-cerebellar pilocytic astrocytomas.

Simona Gaudino1, Francesca Quaglio, Chiara Schiarelli, Matia Martucci, Tommaso Tartaglione, Maria Rosaria Gualano, Giuseppe Maria Di Lella, Cesare Colosimo.   

Abstract

INTRODUCTION: Pilocytic astrocytoma (PA) is classified by the World Health Organization as a grade I tumor. Magnetic resonance imaging (MRI) is the gold standard in the diagnosis and follow-up of this neoplasm, and assessment of contrast enhancement (CE) pattern is essential. The purpose of this study was to investigate CE changes of non-cerebellar PA (n-C PA) stable in size with serial MRI.
METHODS: Nine hundred and twelve MRI exams of 140 children with histologically proven PA were retrospectively reviewed. Patients were chosen for study inclusion if they were off therapy, without neurofibromatosis type 1, and without dimensional changes of tumor/residual tumor. In patients with CE changes, tumor size and CE size were calculated with a cross product. Descriptive statistics were calculated for continuous variables; effects of possible factors influencing changes of contrast-enhanced areas were tested.
RESULTS: Of 39 n-C PA satisfying the inclusion criteria, 12 showed CE changes in terms of appearance/increase or disappearance/decrease of CE areas. Three of these 12 PA were infratentorial and nine supratentorial. There were no significant correlations between age, gender, tumor localization, tumor size, and modification of CE areas.
CONCLUSION: In our experience, n-C PA may show variable CE over time in the absence of tumor/residual tumor dimension change. We recommend that CE fluctuations alone cannot be considered an indicator of tumor progression/regression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22286205     DOI: 10.1007/s00234-012-1010-3

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  30 in total

1.  Pathologic characteristics of pediatric intracranial pilocytic astrocytomas and their impact on outcome in 3 countries: a multi-institutional study.

Authors:  Tarik Tihan; Ayca Ersen; Ibrahim Qaddoumi; Maher A Sughayer; Sahsine Tolunay; Maysa Al-Hussaini; Joanna Phillips; Nalin Gupta; Patricia Goldhoff; Anu Baneerjee
Journal:  Am J Surg Pathol       Date:  2012-01       Impact factor: 6.394

Review 2.  Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.

Authors:  Hiroko Ohgaki; Paul Kleihues
Journal:  J Neuropathol Exp Neurol       Date:  2005-06       Impact factor: 3.685

3.  Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin.

Authors:  Mukesh K Sharma; David B Mansur; Guido Reifenberger; Arie Perry; Jeffrey R Leonard; Kenneth D Aldape; Meredith G Albin; Ryan J Emnett; Simon Loeser; Mark A Watson; Rakesh Nagarajan; David H Gutmann
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

4.  Pilocytic astrocytoma: correlation between the initial imaging features and clinical aggressiveness.

Authors:  J A Strong; H P Hatten; M T Brown; J F Debatin; H S Friedman; W J Oakes; R Tien
Journal:  AJR Am J Roentgenol       Date:  1993-08       Impact factor: 3.959

5.  Pilocytic astrocytomas in children: prognostic factors--a retrospective study of 80 cases.

Authors:  Carla Fernandez; Dominique Figarella-Branger; Nadine Girard; Corinne Bouvier-Labit; Joanny Gouvernet; Armando Paz Paredes; Gabriel Lena
Journal:  Neurosurgery       Date:  2003-09       Impact factor: 4.654

6.  Anaplasia in pilocytic astrocytoma predicts aggressive behavior.

Authors:  Fausto J Rodriguez; Bernd W Scheithauer; Peter C Burger; Sarah Jenkins; Caterina Giannini
Journal:  Am J Surg Pathol       Date:  2010-02       Impact factor: 6.394

7.  A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma.

Authors:  Christoph Burkhard; Pier-Luigi Di Patre; Danielle Schüler; Georges Schüler; M Gazi Yaşargil; Yasuhiro Yonekawa; Urs M Lütolf; Paul Kleihues; Hiroko Ohgaki
Journal:  J Neurosurg       Date:  2003-06       Impact factor: 5.115

8.  Perfusion-sensitive MRI of pilocytic astrocytomas: initial results.

Authors:  Sylvie D Grand; Stéphane Kremer; Irène M Tropres; Dominique M Hoffmann; Stephan J Chabardes; Virginie Lefournier; François R Berger; Caroline Pasteris; Alexandre Krainik; Basile M Pasquier; Michel Peoch; Jean François Le Bas
Journal:  Neuroradiology       Date:  2007-05-26       Impact factor: 2.804

9.  Potential prognostic factors of relapse-free survival in childhood optic pathway glioma: a multivariate analysis.

Authors:  M Y Chan; A P Foong; D M Heisey; W Harkness; R Hayward; A Michalski
Journal:  Pediatr Neurosurg       Date:  1998-07       Impact factor: 1.162

Review 10.  Pediatric low-grade gliomas and the need for new options for therapy: Why and how?

Authors:  Ibrahim Qaddoumi; Iyad Sultan; Alberto Broniscer
Journal:  Cancer Biol Ther       Date:  2009-01-22       Impact factor: 4.742

View more
  13 in total

Review 1.  Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision.

Authors:  Peter M K de Blank; Michael J Fisher; Grant T Liu; David H Gutmann; Robert Listernick; Rosalie E Ferner; Robert A Avery
Journal:  J Neuroophthalmol       Date:  2017-09       Impact factor: 3.042

Review 2.  Current concepts in radiologic assessment of pediatric brain tumors during treatment, part 1.

Authors:  Felice D'Arco; Sinead Culleton; Laurens J L De Cocker; Kshitij Mankad; Jorge Davila; Benita Tamrazi
Journal:  Pediatr Radiol       Date:  2018-07-06

3.  Surveillance magnetic resonance imaging for isolated optic pathway gliomas: is gadolinium necessary?

Authors:  Ezekiel Maloney; A Luana Stanescu; Francisco A Perez; Ramesh S Iyer; Randolph K Otto; Sarah Leary; Lotte Steuten; Amanda I Phipps; Dennis W W Shaw
Journal:  Pediatr Radiol       Date:  2018-05-22

Review 4.  Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.

Authors:  Shivani Ahlawat; Jaishri O Blakeley; Shannon Langmead; Allan J Belzberg; Laura M Fayad
Journal:  Skeletal Radiol       Date:  2019-08-08       Impact factor: 2.199

5.  Migratory enhancement in brain MRI of rosette-forming glioneuronal tumour over 11 years.

Authors:  Bin Chen; Huiyuan Chen; Huanguang Liu; Weibin Gu; Zaiqiang Zhang
Journal:  Acta Neurol Belg       Date:  2022-03-19       Impact factor: 2.396

Review 6.  MR imaging of brain pilocytic astrocytoma: beyond the stereotype of benign astrocytoma.

Authors:  Simona Gaudino; Matia Martucci; Rosellina Russo; Emiliano Visconti; Emma Gangemi; Francesco D'Argento; Tommaso Verdolotti; Libero Lauriola; Cesare Colosimo
Journal:  Childs Nerv Syst       Date:  2016-10-18       Impact factor: 1.475

7.  Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group.

Authors:  Joann L Ater; Caihong Xia; Claire M Mazewski; Timothy N Booth; David R Freyer; Roger J Packer; Richard Sposto; Gilbert Vezina; Ian F Pollack
Journal:  Cancer       Date:  2016-04-08       Impact factor: 6.860

8.  Rosette-forming Glioneuronal Tumor: Rare Case Presented with Spontaneous Disappearance of Contrast Enhancement.

Authors:  Shinya Haryu; Ryuta Saito; Masayuki Kanamori; Yukihiko Sonoda; Toshihiro Kumabe; Mika Watanabe; Faruk Tonga; Teiji Tominaga
Journal:  NMC Case Rep J       Date:  2015-03-09

9.  A case of a rosette-forming glioneuronal tumor arising from the pons with disappearance of contrast enhancement.

Authors:  Fumine Tanaka; Megumi Matsukawa; Ryota Kogue; Maki Umino; Masayuki Maeda; Katsunori Uchida; Hiroshi Imai; Toshio Matsubara; Hajime Sakuma
Journal:  Radiol Case Rep       Date:  2019-05-22

10.  Congenital cystic eye associated with a low-grade cerebellar lesion that spontaneously regressed.

Authors:  Maria Giuseppina Cefalo; Giovanna Stefania Colafati; Antonino Romanzo; Alessandra Modugno; Rita De Vito; Angela Mastronuzzi
Journal:  BMC Ophthalmol       Date:  2014-06-17       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.